Rofecoxib – 50 mg

Brand:
Cayman
CAS:
162011-90-7
Storage:
-20
UN-No:
Non-Hazardous - /

Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2 over COX-1 with IC50 values of 0.018 and >15 µM, respectively, for production of prostaglandin E2 (PGE2; Item No. 14010) in CHO cells expressing the recombinant human enzymes.{12018} In vivo, rofecoxib inhibits carrageenan-induced paw edema and hyperalgesia (ID50s = 1.5 and 1.0 mg/kg, respectively), LPS-induced pyresis (ID50 = 0.24 mg/kg), and M. butyricum-induced arthritis (ID50 = 0.74 mg/kg/day per day) in rats. Formulations containing rofecoxib were previously used in the treatment of pain and arthritis.  

 

Available on backorder

SKU: 10010260 - 50 mg Category:

Description

A NSAID that selectively inhibits COX-2 over COX-1 (IC50s = 0.018 and >15 µM, respectively, for production of PGE2 in CHO cells expressing the recombinant human enzymes); inhibits carrageenan-induced paw edema and hyperalgesia (ID50s = 1.5 and 1.0 mg/kg, respectively), LPS-induced pyresis (ID50 = 0.24 mg/kg), and M. butyricum-induced arthritis (ID50 = 0.74 mg/kg per day) in rats


Formal name: 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone

Synonyms:  MK-966

Molecular weight: 314.4

CAS: 162011-90-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Cyclooxygenases||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Neuroscience|Pain Research